Significantly superior ORR in the ITT population

ABRAXANE ORR in NSCLC
aP value based on chi-square test. ITT=intent-to-treat; ORR=overall response rate.
  • Median duration of response was 6.9 months vs 6.0 months
    (95% CI: 5.6-8.0 vs 5.6-7.1, respectively)
  • There was no statistically significant difference in overall survival between the two study arms
A National Comprehensive Cancer Network (NCCN) Category 1 recommendation
bFirst-line albumin-bound paclitaxel (ABRAXANE) + carboplatin for PS 0-1 patients with advanced NSCLC of negative or unknown EGFR mutation and ALK status.
cCategory 1: Based on high-level evidence, there is uniform NCCN® consensus that the intervention is appropriate.
How did the study define overall response rate?
  • ORR was the percentage of patients who had a complete response or partial response as determined by a central independent review committee using RECIST guidelines (Version 1.0)
RECIST=Response Evaluation Criteria in Solid Tumors.
Trial design

Significantly superior ORR in the ITT population

  • Median duration of response was 6.9 months vs 6.0 months (95% CI: 5.6-8.0 vs 5.6-7.1, respectively)
  • There was no statistically significant difference in overall survival between the two study arms
ABRAXANE ORR in NSCLC
aP value based on chi-square test. ITT=intent-to-treat; ORR=overall response rate.
A National Comprehensive Cancer Network (NCCN) Category 1 recommendation
bFirst-line albumin-bound paclitaxel (ABRAXANE) + carboplatin for PS 0-1 patients with advanced NSCLC of negative or unknown EGFR mutation and ALK status.
cCategory 1: Based on high-level evidence, there is uniform NCCN® consensus that the intervention is appropriate.

INDICATION

ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

INDICATION

ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.